The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: A cross-sectional analysis within the Malmö Preventive Project by Leosdottir, Margret et al.
ORIGINAL INVESTIGATION Open Access
The association between glucometabolic
disturbances, traditional cardiovascular risk
factors and self-rated health by age and gender:
A cross-sectional analysis within the Malmö
Preventive Project
Margret Leosdottir
1*, Ronnie Willenheimer
2, Margaretha Persson
3 and Peter M Nilsson
3
Abstract
Background: The increased risk of cardiovascular disease (CVD) in diabetic compared to non-diabetic subjects
seems to decrease with age. Whether this age-related reduction applies to CVD risk factors, and whether it is
limited to established diabetes mellitus (DM) or also applies to pre-diabetic conditions are not well known.
Methods: Using a cross-sectional design we compared the strength of the correlation between glucometabolic
disturbances (by grouping), CVD risk factor burden and self-rated health, in two age groups: middle-aged (57-69
years) and older (70-86 years) subjects, (63% men), participating in the Malmö Preventive Project Re-examination
Study (n = 18,238). Simple (unadjusted) logistic regression analysis was applied to estimate between-group
differences and trends. Interaction analysis was applied to estimate differences between age groups.
Results: CVD risk factor burden and the proportion of subjects reporting poor self-rated health increased with
increasing glucometabolic disturbance for men and women in both age groups (p-trend < 0.0001 for all). The
slope of the trend curve with increasing CVD risk factor burden was significantly steeper for older women than for
older men (p-interaction = 0.002). The slope of the trend curve for poor self-rated health was significantly steeper
for middle-aged than for older men (p-interaction = 0.005), while no difference was observed between the age
groups among women (p-interaction = 0.97).
Conclusions: We found no reduction in risk factor accumulation with increasing glucometabolic disturbance between
middle-aged and older subjects. Our results indicate life-long CVD risk factor clustering with increased glucometabolic
disturbance, and suggest that previously observed age-related reduction in excess CVD risk for subjects with DM might
be due to a survival bias. However, our observations indicate more pronounced risk factor clustering and worse self-
rated health with increased glucometabolic disturbance in older women than in older men.
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Background
Diabetes mellitus (DM) is a well-established risk factor
for cardiovascular disease (CVD). The Framingham
Study was the first to describe a 2-3 fold increase in the
risk of CVD in diabetic compared to non-diabetic sub-
jects, with women bearing a disproportionate burden of
the risk [1]. Fasting glucose level below the diabetes
threshold has also been shown to be a risk factor for
CVD [2]. Prevention and treatment of glucometabolic
disturbances is thus important, and has been recom-
mended as a means of reducing the future risk of CVD
complications [3].
The incidences of glucometabolic disturbances and
CVD increase with age. However, it has been shown
that the increased incidence of CVD in diabetic
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with increasing age [4]. Whether this age-related reduc-
tion is limited to those with established DM or also
applies to subjects with pre-diabetic conditions is less
well known. Also, studies focusing on gender differences
are lacking. It is important to explore these aspects as
they could affect treatment strategies. In the current
analysis we compared the strength of the correlation
between glucometabolic status - defined by fasting
plasma glucose (FPG) value and a clinical diagnosis of
impaired glucose metabolism - and CVD risk factors, in
two age groups (middle-aged and older) of men and
women, participating in the Malmö Preventive Project
Re-examination Study. We hypothesized that a corre-
sponding age-related reduction would be observed
across the spectrum of glucometabolic disorders. As a
perceived measure of health we also examined whether
the strength of the correlation between glucometabolic
s t a t u sa n ds e l f - r a t e dh e a l t h( S R H )d i f f e r e db e t w e e nt h e
age groups.
Methods
The Malmö Preventive Project was a population-based
cohort study conducted between 1974 and 1992. The
project was a preventive case-finding program with the
aim of screening for CVD risk factors, alcohol abuse
and breast cancer in the population [5]. Birth cohorts of
inhabitants of Malmö, the third largest city in Sweden,
were invited to participate (men born in the years 1921,
1926-42, 1944, 1946 and 1948-9; women born in 1926,
1928, 1930-6, 1938, 1941-2 and 1949). Approximately
33,000 individuals participated (71% participation rate)
of whom two-thirds were men. The screening process
has been described in detail elsewhere [5,6].
The Malmö Preventive Project Re-examination Study
was conducted at Skåne University Hospital in Malmö
during the period 2002-2006. The target population
consisted of the approximately 25,000 individuals in the
original Malmö Preventive Project cohort, still alive and
living in the Malmö area. In total, 18,238 subjects parti-
cipated (63% men) giving a participation rate of approxi-
mately 72%. At the first visit the subjects were given
verbal information on the study, and blood samples
were drawn (after overnight fasting). Laboratory tests
included FPG, serum (s-) total cholesterol, s-triglycerides
and s-high-density lipoprotein (Beckman Coulter LX20,
Beckman Coulter Inc., Brea, USA). Low-density lipopro-
tein cholesterol was calculated using the Friedewald for-
mula [7]. Whole blood was drawn and stored in a
biobank for later genetic analyses [8]. At the second
visit (a week later) blood pressure and pulse rate were
measured twice in the supine position after 5 minutes’
rest, by trained nurses. Height (m) and weight (kg) were
measured in light indoor clothing without shoes. Waist
and hip circumference (cm) were measured. The partici-
pants then answered a questionnaire on lifestyle, self-
assessment of health, limited medical history, and medi-
cation. If the FPG measured at the first visit was ele-
vated (≥ 7.0 mmol/L), new blood samples were drawn
on the second visit. In a sub-sample of participants (n =
1792) echocardiography and ECG recording were per-
formed, and levels of s-Nt proBNP, s-cystatin C and
HbA1c were measured at a separate visit [9].
Data quality was high, with missing values ranging
from 0.1% (laboratory measures) to 0.5% (anthropo-
metric measures, blood pressure and pulse rate) to 1.5%
(questionnaire data). All participants received informa-
tion on the results of their laboratory tests and blood
pressure measurements, and were offered an appoint-
ment with a physician in cases of new-onset type-2 DM
(T2DM), dyslipidemia or hypertension, if they did not
have a personal family physician.
The Ethics Committee of Lund University, Sweden,
approved the Malmö Preventive Project Re-examination
Study (No. LU 244-02). The study complied with the
Declaration of Helsinki. All participants signed an
informed consent form before entering the study.
Description of variables
In the current study, the subjects were divided into six
groups according to glucometabolic status. In the first
three groups the FPG was within the normal range (≤
5.0 mmol/L; 5.1-5.5 mmol/L; 5.6-6.0 mmol/L). The 4
th
group constituted subjects with impaired fasting glucose
(IFG) according to the World Health Organization
(WHO) criteria (FPG 6.1-6.9 mmol/L) [10], the 5
th sub-
jects with new-onset T2DM, and the 6
th group patients
with established DM (T1DM or T2DM). DM was classi-
fied as established if self-reported in the questionnaire
(T1DM or T2DM) and/or if the subject was taking pre-
scription drugs for DM. New-onset T2DM was defined
by two separate FPG values ≥ 7.0 mmol/L [10]. Addi-
tionally, a single measurement ≥ 11.1 mmol/L was clas-
sified as new-onset DM. One measurement of FPG 7.0-
11.0 mmol/L (the second measurement being ≤ 6.9
mmol/L) was included in the 4
th group. This was done
to maximize the benefit of having two separate measure-
ments and thus minimize the risk of mis-classification.
Five CVD risk factors were chosen for this study: the
presence of uncontrolled hypertension, dyslipidemia,
central obesity, current smoking and lack of physical
activity. Uncontrolled hypertension was defined as systo-
lic blood pressure ≥ 140 mmHg and/or diastolic blood
pressure ≥ 90 mmHg, irrespective of hypertension treat-
ment. Dyslipidemia was defined as at least one of the
following: total cholesterol ≥ 5.0 mmol/L, low-density
lipoprotein ≥ 3.0, triglycerides ≥ 1.7 mmol/L and/or
high-density lipoprotein < 1.0 mmol/L for men and <
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Page 2 of 91.3 mmol/L for women. Central obesity was defined as a
waist circumference of ≥ 102 cm for men and ≥ 88 cm
for women. These limits were based on the European
Society of Cardiology guidelines for CVD prevention
(blood pressure, total cholesterol, low-density lipopro-
tein) and classification of the metabolic syndrome (tri-
glycerides, high-density lipoprotein, waist circumference)
[11,12]. Current smoking and physical activity were self-
reported in the questionnaire. Those reporting no lei-
sure time physical activity were classified as being physi-
cally inactive. SRH was measured by questionnaire using
the standardized question: “Would you say that in gen-
eral your health is... excellent, very good, good, fair or
poor?” [13]. Subjects were classified as having low SRH
when answering fair or poor.
Statistical analysis
All calculations were stratified by gender and age: mid-
dle-aged (57-69 years) and older (70-86 years). The pro-
portions (%) of subjects having at least three of the five
selected risk factors and low SRH were calculated for
each of the six glucometabolic status groups described
above. Differences in proportions between age groups
within each glucometabolic status group were calculated
by using simple (unadjusted) logistic regression, generat-
ing odds ratios (OR) and 95% confidence intervals (95%
CI). To assess the strength of the correlation between
increasing glucometabolic disturbance and increased
risk factor burden and worse SRH, logistic regression
analysis was used to calculate beta (b)-coefficients for
trends from the 1
st to the 6
th group for SRH and from
the 1
st to the 5
th group for the risk factors. The 6
th
g r o u p( e s t a b l i s h e dD M )w a se x c l u d e di nt h el a t t e rc a s e
as non-linearity could be expected, as the result of bet-
ter diagnosis and treatment of risk factors for subjects
with established DM. Ratios between the b-coefficients
obtained from the trend analyses were then calculated,
and interaction analysis was performed to estimate dif-
ferences between the age groups, by entering variable A
*variable B into the regression analysis. A traditional
double-sided significance level of p < 0.05 was used.
Baseline characteristics are presented as means ± stan-
dard deviations and percentages. The SPSS 19.0 compu-
ter package was used for statistical analysis (SPSS Inc,
IL, USA).
Results
The total Malmö Preventive Project Re-examination
Study cohort (n = 18,238) was used in this study.
Twelve non-diabetic subjects lacked FPG values and
could thus not be categorized. Baseline characteristics
for men and women are given in Table 1. For simplifica-
tion, data from the first three glucometabolic groups
were combined in the table as these subjects all had
normal fasting glucose (NFG) levels.
Risk factor burden
The proportions (%) of subjects within each glucome-
tabolic status group and age group having at least
three of the five selected risk factors are shown in Fig-
ures 1 (men) and 2 (women). For the whole cohort
and each glucometabolic group, women in general
exhibited more risk factors than men, also after adjust-
ment for age. There was a highly significant trend
among both men and women for increasing risk factor
burden from the 1
st through the 5
th glucometabolic
group in both age groups (p-trend < 0.0001). The ratio
between the b-coefficients from the trend tests (reflect-
ing the slope of the curve) for middle-aged vs. older
men was 1.21 (p-interaction = 0.12) and for women
0.97 (p-interaction = 0.78). Although the difference in
trends between age groups was not significant among
men, older subjects with FPG = 5.1-5.5 mmol/L (OR
0.78 (95% CI 0.67-0.92) p = 0.002), IFG (0.80 (0.67-
0.96), p = 0.02), new-onset T2DM (0.37 (0.22-0.65), p
= 0.0004) and established DM (0.78 (0.62-0.98), p =
0.03) had significantly fewer risk factors than the mid-
dle-aged subjects in the respective groups. No such
differences between age groups were seen among
women. The ratio between b-coefficients for middle-
aged women vs. middle-aged men was 1.19 (p-interac-
tion = 0.11) while for older women vs. older men it
was 1.49 (p-interaction = 0.002).
Self-rated health
The proportions (%) of subjects within each glucose
group and age group reporting low SRH are presented
in Figures 3 (men) and 4 (women). On average, women
and older subjects of both sexes more often reported
low SRH. The middle-aged men with NFG (first three
groups) and IFG (4
th group) reported significantly better
S R Ht h a no l d e rm e ni nt h e s eg r o u p s ,w h i l et h e r ew a s
no difference in SRH between middle-aged and older
men with new-onset and established DM. Consequently,
the trend from the 1
st to the 6
th groups for the middle-
aged men was stronger (b-coefficient = 0.21, p-trend <
0.0001) than for the older men (b-coefficient = 0.11, p-
trend < 0.0001), giving a ratio of 1.89 (p-interaction =
0.005). For women, the b-coefficient for middle-aged
women was 0.17 (p-trend < 0.0001) compared to 0.14
(p-trend < 0.0001) for older women; the ratio being 1.22
(p-interaction = 0.47). The differences in b-coefficients
between men and women in each age group were not
statistically significant (middle-aged: b-coefficient ratio
0.82, p-interaction = 0.33; older: b-coefficient ratio 1.26,
p-interaction = 0.47).
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In this population-based cohort study of middle-aged
and older subjects, we observed that CVD risk factor
burden increased linearly with increasing glucometabolic
disturbance among men and women in both age groups.
The slope of the trend curve was not significantly stee-
per for middle-aged than older subjects of either sex,
indicating that there was no significant attenuation of
the relation between increasing glucometabolic distur-
bance and CVD risk factor burden with age. However,
older men with IFG, new-onset DM and established
DM had significantly fewer risk factors than middle-
aged men in the corresponding glucometabolic status
groups; no such difference was observed among women.
Consequently, the slope of the trend curve was
significantly steeper for older women than older men,
indicating a higher risk factor accumulation with
increasing glucometabolic disturbance among the older
women. We observed that older subjects of both gen-
ders reported worse SRH than middle-aged subjects.
This difference decreased with increasing glucometa-
bolic disturbance among men, but not among women.
Although the excess CVD risk due to DM in women
compared to men seems to have declined since first
described by the Framingham investigators in the 1970s,
recent studies still show that women bear a dispropor-
tionate part of the DM-related excess risk [14,15]. There
have been speculations as to the reasons for this differ-
ence. In the INTERHEART study, DM contributed
more to the population-attributable risk of myocardial
Table 1 Baseline characteristics (presented as means ± SD and percentages (%)) of the participants in the Malmö
Preventive Project Re-examination Study.
Middle-aged (57-69 years) Older (70-86 years)
Men (N = 11,546) NFG IFG New-onset
DM
Established
DM
NFG IFG New-onset
DM
Established
DM
Number (%) 4977
(70)
1299
(18)
158 (2) 721 (10) 3002
(68)
777 (18) 85 (2) 527 (12)
Mean age (years) 64 ± 4 64 ± 4 63 ± 3 65 ± 3 75 ± 3 75 ± 3 74 ± 3 75 ± 3
SBP (mmHg) 143 ±
19
150 ±
19
157 ± 20 148 ± 19 145 ±
19
152 ±
20
151 ± 23 148 ± 20
DBP (mmHg) 84 ± 11 88 ± 10 90 ± 10 84 ± 10 83 ± 11 85 ± 10 86 ± 11 81 ± 11
Waist circumference (cm) 97 ± 10 102 ±
11
108 ± 12 105 ± 12 97 ± 10 102 ±
10
104 ± 9 103 ± 11
Total cholesterol (mmol/L) 5.5 ± 1.0 5.6 ± 1.1 5.7 ± 1.1 4.8 ± 1.1 5.4 ± 1.0 5.3 ± 1.0 5.3 ± 1.0 4.7 ± 1.0
LDL (mmol/L) 3.7 ± 0.9 3.7 ± 1.0 3.7 ± 1.0 3.0 ± 0.9 3.5 ± 0.9 3.4 ± 0.9 3.3 ± 0.9 2.9 ± 0.9
HDL (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.3 1.2 ± 0.3
Triglycerides (mmol/L) 1.2 ± 0.8 1.5 ± 1.1 2.1 ± 1.6 1.7 ± 1.3 1.1 ± 0.6 1.4 ± 0.8 1.7 ± 0.9 1.5 ± 0.9
Current smoker (%) 21.1% 21.1% 25.3% 17.3% 13.5% 13.3% 15.3% 10.4%
Physically inactive (%) 8.5% 10.9% 21.7% 16.9% 9.4% 11.9% 15.5% 18.8%
Using medication for CVD or HTN
(%)
35% 44% 45% 75% 53% 62% 65% 84%
Women (N = 6680)
Number (%) 2979
(84)
331 (9) 28 (1) 202 (6) 2517
(80)
333 (11) 45 (1) 245 (8)
Mean age (years) 66 ± 4 66 ± 3 67 ± 2 67 ± 3 73 ± 3 74 ± 3 74 ± 3 74 ± 3
SBP (mmHg) 140 ±
20
146 ±
20
147 ± 23 145 ± 21 146 ±
21
151 ±
22
157 ± 24 146 ± 20
DBP (mmHg) 82 ± 10 85 ± 11 86 ± 9 82 ± 10 82 ± 10 85 ± 11 87 ± 11 81 ± 10
Waist circumference (cm) 86 ± 11 93 ± 12 100 ± 13 97 ± 14 86 ± 11 93 ± 12 97 ± 11 96 ± 13
Total cholesterol (mmol/L) 6.0 ± 1.0 6.0 ± 1.0 6.2 ± 1.4 5.3 ± 1.1 6.0 ± 1.1 5.9 ± 1.1 6.2 ± 1.2 5.1 ± 1.0
LDL (mmol/L) 3.9 ± 1.0 3.9 ± 0.9 4.1 ± 1.3 3.2 ± 0.9 3.8 ± 1.0 3.7 ± 1.0 4.0 ± 1.0 3.0 ± 0.9
HDL (mmol/L) 1.6 ± 0.4 1.4 ± 0.4 1.2 ± 0.3 1.4 ± 0.4 1.7 ± 0.4 1.5 ± 0.5 1.3 ± 0.4 1.4 ± 0.4
Triglycerides (mmol/L) 1.1 ± 0.6 1.5 ± 0.7 2.1 ± 0.9 1.6 ± 1.6 1.2 ± 0.5 1.4 ± 0.7 1.8 ± 0.9 1.6 ± 0.9
Current smoker (%) 18.5% 21.1% 21.4% 14.4% 12.2% 15.3% 11.1% 11.4%
Physically inactive (%) 8.0% 11.3% 21.4% 19.3% 11.5% 20.4% 27.3% 20.4%
Using medication for CVD or HTN
(%)
32% 51% 54% 69% 48% 59% 49% 82%
NFG, normal fasting glucose; IFG, impaired fasting glucose; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density
lipoprotein, LDL, low-density lipoprotein; HDL, high-density lipoprotein; CVD, cardiovascular disease; HTN, hypertension.
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Page 4 of 9Figure 1 Proportion of men with three or more risk factors. The figure shows the proportion of men with three or more of the following
risk factors: uncontrolled hypertension, dyslipidemia, central obesity, current smoker or being physically inactive; in each of the six
glucometabolic status groups defined in the text. b-coefficients and p-values for trends from the 1
st to the 5
th groups are also shown. Brackets
denote differences between age groups within each glucometabolic status group: * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 2 Proportion of women with three or more risk factors. The figure shows the proportion of women with three or more of the
following risk factors: uncontrolled hypertension, dyslipidemia, central obesity, current smoker or being physically inactive; in each of the six
glucometabolic status groups defined in the text. b-coefficients and p-values for trends from the 1
st to the 5
th groups are also shown.
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Page 5 of 9Figure 3 Proportion of men reporting low self-rated health. The figure shows the proportion of men reporting low SRH for each of the six
glucometabolic status groups defined in the text. b-coefficients and p-values for trends from the 1
st to the 6
th groups are also shown. Brackets
denote differences between age groups within each glucometabolic status group. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 4 Proportion of women reporting low self-rated health. The figure shows the proportion of women reporting low SRH for each of
the six glucometabolic status groups defined in the text. b-coefficients and p-values for trends from the 1
st to the 6
th groups are also shown.
Brackets denote differences between age groups within each glucometabolic status group. * p < 0.05.
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Page 6 of 9infarction in women than men [16]. Disparities in diag-
nosis and treatment of CVD, as well as gender-related
differences in response to treatment have been another
suggested explanation [17]. It has also been suggested
that there is a higher CVD risk factor burden in diabetic
women than in diabetic men [18]. Our study confirms
this, but women in all glucometabolic status groups in
both age groups exhibited more CVD risk factors than
m e n .T h es a m et r e n dw a so b s e r v e df o rS R H ,i ni t s e l fa
strong predictor of all-cause and disease-specific mortal-
ity, also among subjects with DM [19-21].
We have not been able to find any studies reporting
age- and gender-stratified CVD risk ratios or risk factor
burdens across the spectrum of glucometabolic distur-
bances. Several studies on CVD risk ratios between dia-
betic and non-diabetic subjects have, however, been
reported, some of which have presented gender-specific,
age-stratified results. A Norwegian study on coronary
heart disease mortality showed a decline in risk ratio
from the youngest (< 60 years) to the oldest (> 80 years)
a g eg r o u p s ,e q u a l l ys of o rm e na n dw o m e n[ 4 ] .I nt h e
Nurses Health Study, however, only a minimal differ-
ence in coronary heart disease mortality risk ratios was
found between women with and without DM in the age
ranges 55-64 vs. > 65 years [22]. Likewise, in the
NHANES survey from 1999, coronary heart disease
mortality risk ratios between diabetic and non-diabetic
men halved between the age groups 55-64 years and 65-
74 years, while they remained unchanged for women
[23]. Although we analyzed surrogate enpoints cross-
sectionally in the present study, and it is therefore not
fully comparable to these studies, our results concur
with the two latter studies regarding subjects with DM
only. As such, the older men with new-onset and estab-
lished DM had significantly fewer risk factors than mid-
dle-aged men in the respective groups while no such
difference was seen among the women. This lack of age-
related reduction in risk factor clustering and subse-
quently hypothetical risk of CVD morbidity/mortality
among diabetic women may make a contribution to the
observed difference in excess CVD risk for diabetic
women compared to men.
In our study, the risk factor burden increased signifi-
cantly across the glucometabolic status groups for men
and women in both age groups. Although there were
significant differences between middle-aged and older
men with IFG, new-onset and established DM as dis-
cussed above, the difference in trends for risk factor
accumulation across glucometabolic status groups
between the two age groups was not significant for
either sex. This discrepancy might reflect a survival bias,
in that subjects with glucometabolic disturbances
experience a life-long tendency for risk factor clustering
while those with the most serious metabolic
disturbances succumb to CVD events at an earlier age.
However, it should be noted that the trend was signifi-
cantly weaker among older men than older women, who
showed an accumulation of risk factors with increasing
glucometabolic disturbance to the same degree as both
middle-aged women and men. These results support the
fact that not only women with DM but also prediabetic
women, irrespective of age, need special attention when
screening for and treating concomitant CVD risk
factors.
The major strength of this study is that it examines
the association between CVD risk factor profile and
degree of glucometabolic disturbance through the
range from NFG to IFG and DM, in a large popula-
tion-based cohort, allowing comparison between differ-
ent groups and the assessment of trends and
interactions. The participation rate in the study was
high (72%) and missing values were few, increasing the
validity of the results.
There are some limitations in this study. Firstly, as
with all population-based cohort studies, there is risk of
a “healthy cohort” effect, meaning that subjects with co-
morbidities, disabilities or poor quality of life might
either have died or been too weak to participate in the
study. As these subjects would be more likely to be
older and classified in the groups of subjects with higher
glucometabolic disturbances, such a bias would lead to
underestimation of CVD risk factor burden and poor
SRH in those groups. A study on attendees versus non-
attendees was performed in the original Malmö Preven-
tive Project, showing that total and cause-specific mor-
tality was higher in non-participants than in those
participating in the study [6]. It can be assumed that
similar findings would be found in the Malmö Preven-
tive Project Re-examination Study. Secondly, it cannot
be ruled out that some non-fasting values were used for
the classification of glucometabolic disturbances. Also,
no oral glucose tolerance test was performed. This
might have led to mis-classification of glucometabolic
disturbances and underestimation of glucometabolic-
related risk, especially for women as impaired glucose
tolerance and DM defined by an oral glucose tolerance
test is more common among women than men [3].
Thirdly, the duration of diabetes was not considered in
this study. Other studies have shown that subjects with
early-onset DM run a higher risk of CVD than those
who develop the disease in middle age [22,24]. Gender
differences in the three above-mentioned limitations,
which would have led to a biased result, cannot be ruled
out. Regarding risk factors for CVD rather than CVD
morbidity and mortality limits the conclusions that can
be drawn concerning the clinical relevance of the
results. Furthermore, no conclusions about causality can
be drawn from a cross-sectional study.
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Page 7 of 9In conclusion, the previously observed age-related
reduction in elevated risk of CVD in diabetic compared
to non-diabetic subjects was not observed for risk factor
accumulation with increasing glucometabolic distur-
bance. Our results indicate life-long risk factor cluster-
ing with increasing glucometabolic disturbance, while an
age-related CVD risk attenuation with respect to DM
might be due to a survival bias. However, our observa-
tions suggest a more pronounced risk factor clustering
and a more negative effect on SRH with increasing glu-
cometabolic disturbance in older women than in older
men. These results may contribute to the previously
observed higher risk of CVD in women with glucometa-
bolic disturbances than in men. The results also indicate
the need to pay special attention to screening for and
treating concomitant CVD risk factors among women
with glucometabolic disturbances, irrespective of age.
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